Use of Imaging and Diagnostic Procedures After Low-Dose CT Screening for Lung Cancer
- PMID: 31521671
- PMCID: PMC7005377
- DOI: 10.1016/j.chest.2019.08.2187
Use of Imaging and Diagnostic Procedures After Low-Dose CT Screening for Lung Cancer
Abstract
Background: Clinical trials have demonstrated a mortality benefit from lung cancer screening by low-dose CT (LDCT) in current or past tobacco smokers who meet criteria. Potential harms of screening mostly relate to downstream evaluation of abnormal screens. Few data exist on the rates outside of clinical trials of imaging and diagnostic procedures following screening LDCT. We describe rates in the community setting of follow-up imaging and diagnostic procedures after screening LDCT.
Methods: We used Clinformatics Data Mart national database to identify enrollees age 55 to 80 year who underwent screening LDCT from January 1, 2016, to December 31, 2016. We assessed rates of follow-up imaging (diagnostic chest CT scan, MRI, and PET) and follow-up procedures (bronchoscopy, percutaneous biopsy, thoracotomy, mediastinoscopy, and thoracoscopy) in the 12 months following LDCT for lung cancer screening. We also assessed these rates in an age-, sex-, and number of comorbidities-matched population that did not undergo LDCT to estimate rates unrelated to the screening LDCT. We then reported the adjusted rate of follow-up testing as the observed rate in the screening LDCT population minus the rate in the non-LDCT population.
Results: Among 11,520 enrollees aged 55 to 80 years who underwent LDCT in 2016, the adjusted rates of follow up 12 months after LDCT examinations were low (17.7% for imaging and 3.1% for procedures). Among procedures, the adjusted rates were 2.0% for bronchoscopy, 1.3% for percutaneous biopsy, 0.9% for thoracoscopy, 0.2% for mediastinoscopy, and 0.4% for thoracotomy. Adjusted rates of follow-up procedures were higher in enrollees undergoing an initial screening LDCT (3.3%) than in those after a second screening examination (2.2%).
Conclusions: In general, imaging and rates of procedures after screening LDCT was low in this commercially insured population.
Keywords: LDCT; NLST; chest imaging; computed tomography; follow up; health-care utilization; imaging; lung cancer screening; procedures.
Copyright © 2019 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.
Figures


Comment in
-
Diagnostic Evaluation After Lung Cancer Screening in Real-World Practice: More Questions Than Answers.Chest. 2020 Feb;157(2):247-248. doi: 10.1016/j.chest.2019.10.028. Chest. 2020. PMID: 32033643 No abstract available.
-
Novelties in Lung Cancer Screening.Am J Respir Crit Care Med. 2021 Sep 1;204(5):596-598. doi: 10.1164/rccm.202012-4505RR. Am J Respir Crit Care Med. 2021. PMID: 34213386 No abstract available.
Similar articles
-
Complication Rates and Downstream Medical Costs Associated With Invasive Diagnostic Procedures for Lung Abnormalities in the Community Setting.JAMA Intern Med. 2019 Mar 1;179(3):324-332. doi: 10.1001/jamainternmed.2018.6277. JAMA Intern Med. 2019. PMID: 30640382 Free PMC article.
-
Utility of FDG PET/CT for assessment of lung nodules identified during low dose computed tomography screening.BMC Med Imaging. 2020 Jun 22;20(1):69. doi: 10.1186/s12880-020-00469-0. BMC Med Imaging. 2020. PMID: 32571221 Free PMC article.
-
Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.JAMA. 2021 Mar 9;325(10):971-987. doi: 10.1001/jama.2021.0377. JAMA. 2021. PMID: 33687468
-
Dose exposure in the ITALUNG trial of lung cancer screening with low-dose CT.Br J Radiol. 2012 Aug;85(1016):1134-9. doi: 10.1259/bjr/20711289. Epub 2011 Oct 5. Br J Radiol. 2012. PMID: 21976631 Free PMC article. Clinical Trial.
-
New evidence supporting lung cancer screening with low dose CT & surgical implications.Eur J Surg Oncol. 2020 Jun;46(6):982-990. doi: 10.1016/j.ejso.2020.02.015. Epub 2020 Feb 19. Eur J Surg Oncol. 2020. PMID: 32113886 Review.
Cited by
-
Positive Screens Are More Likely in a National Lung Cancer Screening Registry Than the National Lung Screening Trial.J Am Coll Radiol. 2025 Jun;22(6):644-652. doi: 10.1016/j.jacr.2025.02.012. Epub 2025 Feb 27. J Am Coll Radiol. 2025. PMID: 40023436
-
Propensity-score-matching analysis to compare efficacy and safety between 16-gauge and 18-gauge needle in ultrasound-guided biopsy for peripheral pulmonary lesions.BMC Cancer. 2021 Apr 9;21(1):390. doi: 10.1186/s12885-021-08126-7. BMC Cancer. 2021. PMID: 33836683 Free PMC article.
-
Serum levels of retinol-binding protein 4 and the risk of non-small cell lung cancer: A case-control study.Medicine (Baltimore). 2020 Jul 31;99(31):e21254. doi: 10.1097/MD.0000000000021254. Medicine (Baltimore). 2020. PMID: 32756103 Free PMC article.
-
Rates of Downstream Procedures and Complications Associated With Lung Cancer Screening in Routine Clinical Practice : A Retrospective Cohort Study.Ann Intern Med. 2024 Jan;177(1):18-28. doi: 10.7326/M23-0653. Epub 2024 Jan 2. Ann Intern Med. 2024. PMID: 38163370 Free PMC article.
-
Effects of pre-operative biopsy on recurrence and survival in stage I lung adenocarcinoma patients in China.ERJ Open Res. 2023 Aug 14;9(4):00675-2022. doi: 10.1183/23120541.00675-2022. eCollection 2023 Jul. ERJ Open Res. 2023. PMID: 37583968 Free PMC article.
References
-
- Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. - PubMed
-
- Moyer V.A., US Preventive Services Task Force Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5):330–338. - PubMed
-
- NELSON study shows CT screening for nodule volume management reduces lung cancer mortality by 26 percent in men [press release]. IASLC 19th World Conference on Lung Cancer (WCLC). September 25, 2018.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous